                           ˿µϣ20100102գ

10.01.01ûи
10.01.02, Ϻ顰Leibnizеá
10.01.02, šӦũҵѧԭУȻҪ˵ʦ
10.01.02, ɡڽѧΪԭָҽҩߵרѧУĽ鰸
10.01.02, james_hussein_bondФڸ
10.01.02, 㡶ѧݽͨѧѧԺԺĿ
10.01.02, jxhɽѧøá
10.01.02, rtԷɾɽѧĲ䡷
10.01.02, ΡΪҽ汳˵ѣϳν̵ˣ
10.01.02, ¼뵽ġ
10.01.02, 󺣡ɡϴѧֹڹϵͳǡ뵽㽭ѧУ
10.01.02, ˮߵƻй̬谷
10.01.02, cocktailֵºӢ¡
10.01.02, ġǻеĺֳɷ֡
10.01.02, ˵¡ַҽ¹ʡ
10.01.02, ӡ汨ͷĳϮ
10.01.02, ԺרһӦܲĹɣҵʿ˵л

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

Ϻ顰Leibnizе

ߣ

2009107պ109գվ˿Ⱥ󿯳ѧУ
ԺʿʲôʱùLeibniz𣩺͡ԺʿĵһͰ𡷣
ӣ¶Ϻط־ء1988¹Leibniz
ΪеĻԣԴͷΪԼ˿1112
УΪ⣬١¼רй£
ѯ̬ǰϾʧȴһУԴ˳
Ĭÿǵ˶Լжϣ˵λҼѧ
ͷѳɵķʹѡֵǸ
㿴ǵĵһֱԡLeibnizϡЦ
˼Ϊȴɵί쵼Żڸѧкйص
´ڵУûἰκȽ
ݡμ̱ר÷ӡѧУм١
XYS20091913ͼͬLeibnizиλ쵼źǣ
ѧ棬»Ϻ199210·еġѧ
¼³ơ¼ǡǡ֤˻Ϊ١

ǱɸУղд棬ǰУндǰԵġ
¼еĵ270271ҳϾӦñλ쵼綨
ġѧкйصļΧСλ쵼֤
ûеġκȽݡ

1987ڵ¹ڼ˴Źڸ߷Ӧã
תͬо߷еĽṹȡͷ˶֮Եһ
ϵ¼оСһ˵¹һ䷢Leibniz󽱡

һʮֿڣʮȷԸȷϡ
Leibniz󽱡ʷϡһ1960ŵǾ
϶1960ŵ϶1960ŵ
￣ѧ¡Ρʷ˹һ˻2009
Ҳ϶￵ŵ¡ŵԼ
ʷ˹ŵ֮Ǳ¼доСһ
˵¹һ䷢Leibniz󽱡Ǹѧԡ1988
Leibniz϶ʸί쵼˵ڸѧ
кйصļûἰκȽݡ


ϧ¼ءоСһLeibnizȫϹ
ࡣڵ¹격ʿ֪¹DFG䷢Leibniz
ǸˣʲôоСģĿòףʦSpiess
˵1988LeibnizôһصйϹд

Ǳ¼дţõǺڵλ쵼֧֣
ѧ˸˵ÿλҵǽԼ
ݣλϵ쵼ˣѧУȷϷһҲ
⣬áϹࡱ1988Leibniz󽱹ǣһ⣺
ڡ¼ǰһ꣬1991걻ְƵġڡ¼
иϹLeibniz£ְλд
LEIBNIZأܲھְλʮҪʱǫһдLeibniz
ھ̹ںõġ¼дɣǲ


ǰƣ1988ع̶Уһ·Ծ1990Ϻ
ͻ֣1991ϺʮƼӢƺţͬҽίͻ
йʿԱҪʣص걨Уд
Leibnizģ˺ѧԺԺʿдLeibnizġԴˣ
ǿϺҽίԱĵʱϣһϵ⡣

鲿ͽ鲿
͹ԺΪѧУģͬһ㡣Ѱ
롰ƭܰλĵˡ壨μSuprathinker
XYS20091220ΪĽʦΪһλѧ粻ǰƵ˵У
вö׿ļѧԺԺڿָ
ʿֱòʿѧλżһ첩ʿǿЦã
ʿܿӦָɵ𣿡XYS20090827ѧ
ϴѧôѧѧѧλȥ
ˡʵ򡰻LeibnizУѾ޷У
ڶѧ磬ʹѧΪУΪΪѧǰ;ͷ
չǣLeibnizЦֵ¹ֵʣԸ
йĴ޷ơˣ

ҽѧ칫ңйѧԺԺʿ쵼Ͽ֯ר
Ŷ1988عһ·УƵġLeibniz
˺ƶã

Ҫ󸴵ѧ쵼ʦѧֶ֧
ðLeibnizĽҷΪһԴվ˿ڶ
ʽķȫУʦ֪ࣻ

ǺѧȫУʦѧɵ˵УΣ
գLeibniz̬ķչ

ҲϣԼΪԸ͹𺦣
ԸʦŵұҲѧܲˣҲϣʦٽ¶
ίУְڶȫУʦһν룬ȫ帴
ʦȫѧ̴ְ

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ӦũҵѧԭУȻҪ˵ʦ

ߣ

˿2009126֮سũҵѧԭУϮN
ƪѧ˾ȻҪоʦ,⵱21йߵ
ˡµԲǷǸУϮҲڳϮ
ܲоڳϮNƪµĵĿǰµĹʵ
ϵеĹؼڡNƪʲô1ƪ5ƪ10ƪ
࡭һĳϮżĳ죿

˰ũҵѧԭУϮĵӺ£֪N
ƪľ庬壬ɴ˿Ըܵɱд巢嵱ʱķŭ顣ѭ
ɱָ֮·ӵҳ˭ųϮNƪĵԭУ
ܼѧѧλ쵼ְܼڡڹûʵо
Ҫȫչʾ䡰ڷɡأ治֪·ѧУѧԺ
ʲôʲô

һҵʦһرְҵ֮һ
ҵΪҵĲƷһʲƷǵ²ż汸ȫ淢չ
˲šڽҵԣԽǽʦرҪ
񹲺͹ʦ͸ߵȽԽʦְʸȷϸ
ܵ˵л񹲺͹ĽʦҪ˼Ʒ¸С
˫ܰ˲ʸ½ʦְҵȻôܲϸ˲أ
ڽڣҪϸҪΪǽʦеľӢ֪кһ
Դ̡Ϊʦ

źǣ£ʡصѧﾹȻ˱سϮNƪĵ˲
ѧⱻϼְ˻ܼѧѧλ쵼ְ
ڡڹо˵ʦⲻʾ
ϮNƪĵ˼ûʲô⡱ϮҲʲô룬
еڶNڳϮN1ƪģ㻹ò
о㲻о᲻˵㲻
ƽ᲻˵ˣźнƽϢˣ
͵ðоȥйĸߵȽ
кϷˣ̨˵ʲôʦĹʦԽʦѧָֻţ
ҪǲϮµĽʦѧȥ
ʲôƽ˹˲ǿҲֻܳΪ̸P

ǲҪʣΪʲôһϮNƪĲϼ쵼ְ
ˣڵλҪͨĿŵشġṦΰҪ
ҵΪʦ⾿ǳڶѧΪĿݣ
Ϊȡ֮٣⾿ںɣǶа
Ĭ˾Ϊءǲ
˵ѵúͿ޵ǴŰ

ɱĽ鲻޲οֵѧ˼ڽڸ
λϡˡԱˡѧУѧᶼ˵һ
顣Ӧ֪֮ɱ˵Ĳ޵йе
Ҫ˻ܶ࣬ũҵѧѧίԱ쵼ɲҪΪЩȱѧµ
Ⱥ֮۽ѧٵѧУԸɣÿ
бֳĬȨųĬǽĻ

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ڽѧΪԭָҽҩߵרѧУĽ鰸

᰸ˣ
ҽҩߵרѧУʦУЭʡίԱϵ绰
13765963366ͨŵַз˱·106ţʱࣺ563002

鰸Ҫ
200081118ϷַӳҽҩߵרѧУУ
ѧΪӣУˡٶȡѺҪ綼
תأֻҪڡٶȡ롰ҽרͿԿߵĵ
ﵽ8000ˣ

2009615գй걨׳ɷ£¶ҽ
ҩߵרѧУѧΪܵѧУίǷĹ̺
Ϊְš¼ݶбתءȫվҲ
˵ءýͱķӰҽҩߵר
ѧУĸӰѾȫ漰㣬Ӱӡ

ҵΪӡҽҩߵרѧУ2006Ϊרѧ
УĿǰ7000ѧٽְԱѧУѧĹؼʱ̣ѧУ
Ҫܽѧ쵼ѧΪѧУίѧ
ΪвΪȫӰѧУͷչˣѧУְֽԱ
ͬʽܲšͼ첿š֯ţ쵼ӳУ
ѧΪԭҪ쵼ΥѴһ࣬ûκ
ʽĻظ

ԣ֯鴦ЭίԱ鴦ọ̈̄ල

һʵ͹̣

200089£֯ϣ걨ڡ

200081115գҽҩߵרѧУӵʡѯ
걨ڲеĸҪѧУش

110δκҽԺ¹ҽƻ30,
ʵ

2,Ƿʵ

3μҵ䡢ĿǷʵ

4дְ̲ͶɣǷ
ʵ

200081117գҽҩߵרѧУѧίԱṲ17Աμӻ飬
ĸѯƣȫѯݲʵѧίԱ
ֱʽһ϶һڶʵ16
δκҽԺ¹ҽƻ30ˣѧί
Աȫ̾⵽ѧУίǷţѧίԱε˷
ʹвȥл¼ȫѧίԱԱ֤

200081118գѧУίڷľ尲£ܿѧУѧίԱ
ѧУίʡߺʵ㣵֤֤ʡ
ѯĸⲻʵͬգѧУѧίԱΡУ˷ɵʡ
´㱨ѧУѧίԱ͹̡

ְ걨类ʡίȫƱ

ʵѧУְֽԱԲͬʽܲšͼ첿š
֯ţ쵼ٱشɲУѧΪԭ
ûκʽĻظۺͽְԱĲԽԽҡ

ڶʵ͹̣

200811£ΪΨһߣĺڿʡҽѧ
ʿ־2322ڣϷΪΰ˵ҽһģ
н65ΰʵʩ˻ᡣ

20093£ҲΨһߣڡҽҩߵרѧУѧ3
1ڣΪΰ˵ҽһģн32
ΰĻҪ㡣

20099£ƪٴ걨ڡ

200992գѧУί걨ְߵĲϣίǷ
绰֪ͨϯ飬ɽ˻ݡڲμ
ѧϰѧϰ飨֮ǰ֪ͨ˵ģȥȥˣ
ɵ绰Ͻ飬ѧУѧίԱ걨ߵĲϽмϱ
ѧίԱ³̹涨ݣûͬ⡣

20091118գҽҩߵרѧУӵ¾תĺ
ʡְƴ͹ʡ´ѯѧУʦ2009ڽ
ְƵ2㣺165ΰ˻32ΰ˻Ҫ2ƪǷ
д2漰ûУǷ죿

20091118գѧУίǷٿ쵼רо¡
˵Ϊ2ƪԼд2ƪݡ
㣺һǸݽ涨ѧӦѧίԱһǲ
ҽƻԭʼǲѧУҪṩԭʼϣ
ṩԭʼϡεһµĸУָ2
ƪд϶µԭʼ⣬ͳһݻᡣ
׼ṩԭʼϵʱ䡣

20091119գмίݽٱţҪǣ
ؼ쵼ɲѧУίԱֹܽѧĸУȥûִҵҽ
ʦ֤30ˣѾѧУӰ죬ֲȡ
òԭʼϾȥġڽ2009319ա֪ͨй涨
ѧΪеͣҪмίʱ飬Թ淶ѧ
Ϊ

20091120գѧУٿѧίԱ飬ʵʵ16ˣ15ˡ
ڻȻһݲҲûṩƣҽԺиΰ
סԺ15ݡΰ˵סԺ12ݣҽԺиΰ˵סԺ
6ݣΰ˵סԺ4ݣ֮ĸΰͷΰ˵ȫ
ԭʼݵġѧУѧίԱн32ΰ˵ĸѨ
λĶλԼнܵ65ΰϱ׼⣬ش
شĸѨλλ3ڸΰϱ׼ش
ѧУѧίԱ15ԱһȷҪṩȥϿ
뿪δμӱԾֱķʽȫһͨ1û֤
֤²дĿǰûнӵдľٱ2
ṩԭʼϵ˵ûṩԭʼϣṩԭʼ
ϺٶʽԵڶⲻۡǲλԱǩѧ
ίԱۣлԭʼ¼

˲ǣ20091120գѧУѧίԱ¾ֵĻظУ
ˡṩԭʼϺٶһ䣻ѧУί¾ֵĻظУ
20091118յĵӻΪ϶3ƪд
ϾµĸУѧίԱְٿѧίԱ
¡

˲ǣ20091121յְΪɲĸУ
Ȼͨʸ飬2008ꡢ2009شɵ걨
һְ߽Ĵ᳡

Ľǣְ걨һαʡίȫƱע
2008һίֻǴӴѧˮƽϽеͶƱ

۵Ĳʣ

11978꿪ʼҽԺ1992ѧУ1992
ԺȷʵûκһҽԺҽƻ200812£Ű
ִҵҽʦ֤ԣ1978굽1992ڼ䣬30ˣ
14ҽ365/㣬ÿӦ59ˣǲʵ
ģҲûԭʼ֧ŵġƣѧУ칫Ҳβˣ
Ϲ涨Ϊִҵҽʦ֤ҲûУ

2Ƿͼһ֪

3μҵ䡢Ŀ2007꾭ѧУѧίԱ֤Ƽ
ʡ걨ĿоݿɲģʱĿԱҲǣȫУ
ѧίԱԱ¡2008꣬ȴΪĿĿˣ
ֱʡ͹ʡ걨ĿǷڽ[2009]3
ļгѧΪĵһ֡ѧɹ

497֢2ƪ£Ȼ2008׺2009ģ
20091118յĵӻ20091120յѧУѧίԱ
ϣһݲҲṩѧУҪṩ
ṩѧУѧίԱȷҪṩԭʼϡǣΪ
ṩµԭʼϣΪϱѧίԱûѧίԱȷҪ
ṩԭʼϵݣΪϱѧУίн20091118
ĻΪһ¾ɸѧίԱΣѧίԱ
£ΪϱѧУίн2ƪд3ƪѧУ
ѧίԱԱʽҽԺҽԺ飬20091120ѧ
ίԱġҽԺиΰ˵סԺ15ݡΰ˵סԺ
12ݣҽԺиΰ˵סԺ6ݣΰ˵סԺ4ݡ
ѡʵǷڽ[2009]3ļгѧ
Ϊĵ֣ʵ

5ʡ2007ꡢ2008ꡢ2009Ĺְƽļжȷ
涨ְƽŪߣ2겻걨ְƽǣְܲ
ȴһֱδ2008걨ְƵѧΪָӦĵ
飬֯ҲδӦĴҲδӦԭʲô

6ΪȺڷӳ֮ɲĸУͬ2008
ꡢ2009شɵ걨ϣͨϸʸģ

7Ϊί֯ƽȺڷӳȵ֮࣬
ûȷ۵£ȴȫУְϣԵίǷ
УĹȫֵĿ϶˷ѽ⣡

Ⱥڷӳ⣺

ⷴӳʱǰһ֮ãزӦòȡ̬ȣ
ʵȺڷӳбҪ߶ӡ

һίŸڽ 2ȴһο

ҽҩߵרѧУίǷǸڣȴŽڵĽ
֪У600Ԫ/£1200Ԫ/£ͬʱ200767
մίУ֮һοҲûϡ

ί飬ֻҪѧУĿγ̱ͽÿµʵʩ
߷÷ϹεѧͿ

ڶίǲμӼ࿼ȴ࿼

ҽҩߵרѧУίǷǸڣûֱӲμӼ࿼ȴ
ȡ࿼20094£ǩͬ⣬1200Ԫ࿼

ί飬ֻҪѧУ´2009μӲ࿼Ա
߷˺زѧ 

ίΥ

2009ϰ꣬ҽҩߵרѧУίǷΥҵλ
ؿԭԴǾƹ˾ҵλҽҩ
רѧУ񴦣ҵλԱչ˽
ΧڵԱȺڷӳн־ֳˡ

ְ飺ѧУְŮѧУʱҵȴòתΪ
ҽҩߵרѧУίǵķȨѧУп޵Ա
Υ涨
ί飬ֻҪµѧУ񴦵򵵰߷ѧУд
ҵŮְ 

ġίΥֹп

20097ѮҽҩߵרѧУίǷˣ֯
п15ʦ͸Ա200977ʱ40ͬ⡣
ʱ涨ǲμԵĿٺ͹Ա뽻ֻ뿪Ŀ
֤й¶ϿԹƽСǣһֻΪ
13017418598ˣڿ֪һݵԵĿ
Կ32š˵μԵĿٺ͹Աйܡ   

ְ飺ҽҩߵרѧУп15ʦ͸Ա
˽ӽ500ˣ30˾һǽְԱŮμӿԱ̭
ʸҲûСοԹƽ

Ҫί飬ֻҪֻΪ13017418598˵ͨѶ¼
߷ѧУְŮμӿԱ̭ʸҲûеְ

塢ίΥ쵼ɲ

ҽרίǷڵҽרίڼ䣨200767
𣩣1µ2007718գѧУίļʽѧУ21
ҵĸ쵼λʱˣļ´֮ǰûУУ
1200879£УУϣй
֯ɲùйŸ˵йع涨е顣

Υϯ

ҽרίǷڵҽרίڼ䣨200767
𣩣1µ2007718գû걨ȡԭѧУ֯Ա
쵼ǰ£ѧУίļʽѧУµĹʱˣļ
֮ǰûУУ1200879£ѧУû
гµĹ֯ѡµĹԱ֮ǰ6£ĽѧУ
ϯˣҲûУУ

л񹲺͹ᷨϯȷ涨йѡ١
֮֯ѧУ֯ѡٹԱ֮ǰ6
¾ĽѧУϯˣ԰ѧУ򱨡
ί֯ƽԴźѡȥίĽ
Ǹǰ̸֯ƽίǷְȷϣѯ
صУУǲûû
ʡ׼ҽר֯ļʱ䣬ҽר
¼¼աл񹲺͹ᷨ

ߡΥ氲Ż 

ίǷ˦л񹲺͹ߵȽڵί쵼У
Ĺ涨У֪ΥУ칫ûбꡢûͶꡢ
ûơƲƲŲ£ѧУίǾ԰ʵʩ̣
ʱȥί֯ѧУ顰ѧ׼
ѧУ򱨡ͼסίΥ̷߽̹
ع涨

ְ飺У֪ΥУ칫ûбꡢûͶꡢ
ûơƲƲŲ£ѧУίǾ԰ʵʩ̡
ί֯ϼָ޽֯Աͬ£ȴ
ҽר ѧУѧ׼ 
У칫¼бꡢͶ򣻲ѧУơƲƲǷ
룻ѧУ0896յġ򱨡 

ڰˡѧУʲҹ˳ⲻý

2009113գڶҹҽҩߵרѧУ㴨Уʽ
յˣûоͬ־֪ûоѧУ쵼о
£ͼУƼݳб걾ټУУ칤
УԱ¡Ϊʱûκν͡

¸죬򷽹ʡҽԺѧУƵǰ̨Ϊ衱

ʣԭ㴨Уʱ걾ܶ࣬ˣϴϪУ˱걾ȥ
ԭ塣£ֻΣһѧУҹǡ
ΪβǴǴ򽻵趫ûнݣشû
лû¶Ų衱Ҫ쵼ùʦ
δðӼδ˸δУȫΧ
걾Դŵ£ĵشУʲǷΥ

ί飬113ձֵ¼ǰѧУ
ڡ

ھšҪ쵼Ů20Ʋշ

ҽҩߵרѧУй涨вĿѧ벹ϸ
ܷҵ֤ǣ08ҵӰרҵ011ѧУ
ҵֶжʮƲ񣬱ҵ֤
Ȼء  ְѧܴ󣬶ѧƽ Ϊֹܽ
ѧĸУȫУѧҳ

ίͲѯĳɼѯԾѯԾ
ıʼڣصĿԱηҵ֤ġ

ıҪԣ

1	 ĿǰҽҩߵרѧУĶĶ
ѧڽһʵǵԭ򣬳ʵ࣬ȫָ
ҽҩߵרѧУĶѧУѧΣΪʱ


2	ѧУǽѧʥأǴ֪ʶĻĵطѧ
иߵԺУְھУ԰һǿѧ罨衢
̷罨У罨衣

3	ڽһнڡ鴦УѧΪļ
Լ鲿̨ʵе쵼ɲй涨йؾ

4	ڽһǿɲ齨衣ڼǿִڹ
ȺĿе쵼λ

飺

᰸漰ĲԱͨϰգһɲ漰Ӱ
ЧӦӣΣ󣬳ʵΪҪǽͺ

1ѧУ͸ɲȨޣɹʡίʡί
мίϵ飬ɹʡЭίԱල飬ѧ
йع涨ͬѧϴڵĲΪֳ٣ѧУ
ѧίԱѧռҲѧУѧίԱ͹
ʡУרһѧռͬʱȺڷ
ӳȵԵ鲢ԭҽҩߵרѧУһ
ľ档

2ѧУ͸ɲȨޣɹʡίʡί
мίϵ飬ɹʡЭίԱල飬
ѧϴڵĲΪ   

3ѧУ͸ɲȨޣɹʡίʡί
мίϵ飬ɹʡЭίԱල飬ɲ
У걨ϴشɵ£˳ͨ
鲢ܲμӴе׷漰˰͹
ദ

20091215

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

Фڸ

ߣjames_hussein_bond

Ф2006European UrologyϵеĿͷηֱThe 
Journal of Urologyƪͬ¡ȻǰƪµǻὲӢĵĹ
ͬ߰дġФдʱûнӢĵĹͬ߰æֻóǰˡ

˵ǰƪǱ˰дģиݵġʱظ
˼ĹĲֳһĶڴ((the) morbidity)ȫ
ԭĸһ2003ԭ˵a major problemûФ
ʱΪǵظĳa major medical and social problem
ˡҽѧӦòͬһ⡣Ӣ̫̫
2005ԭpharmacologicalʡФĳpharmacologicֻһ
˸ĵڶ䡣ȼʽĻãǳһ仰
remainϵģԭҲûе˳ƵsФ
һs˱ŵChinglish

һƪ
An Artificial Somatic-Central Nervous System-Autonomic Reflex 
Pathway for Controllable Micturition After Spinal Cord Injury: 
Preliminary Results in 15 Patients
The Journal of Urology, Volume 170, Issue 4, Pages 1237-1241
C. XIAO, M. DU, C. DAI, B. LI, V. NITTI, W. de GROAT

Neurogenic voiding dysfunction after spinal cord injury (SCI) is a 
major problem. In industrialized nations the mortality related to 
renal problems after SCI has significantly decreased since World War 
II but morbidity has remained significant, chiefly because of poorly 
controlled bladder and bowel functions. In underdeveloped countries 
where medical resources are limited, no significant progress has been 
reported on the mortality and morbidity of survivors of SCI.

ڶƪ
AN ARTIFICIAL SOMATIC-AUTONOMIC REFLEX PATHWAY PROCEDURE FOR 
BLADDER CONTROL IN CHILDREN WITH SPINA BIFIDA
The Journal of Urology, Volume 173, Issue 6, Pages 2112-2116
C. XIAO, M. DU, B. LI, Z. LIU, M. CHEN, Z. CHEN, P. CHENG, X. XUE, 
E. SHAPIRO, H. LEPOR

Abstract
Purpose:
Neurogenic bladder is a major problem for children with spina 
bifida. Despite rigorous pharmacological and surgical treatment, 
incontinence, urinary tract infections and upper tract deterioration 
remain problematic. ......

Neurogenic voiding dysfunction in children with spina bifida is a 
major problem affecting overall health and quality of life. The 
combination of pharmacological agents, surgical bladder augmentation 
and clean intermittent catheterization has limited success. ......

ƪ
Reinnervation for Neurogenic Bladder: Historic Review and 
Introduction of a Somatic-Autonomic Reflex Pathway Procedure for 
Patients with Spinal Cord Injury or Spina Bifida
European Urology, Volume 49, Issue 1, Pages 22-29
C. Xiao

Neurogenic voiding dysfunction after spinal cord injury (SCI) 
presents a major medical and social problem. In industrialized nations 
the mortality related to renal problems after SCI has significantly 
decreased since World War II, but the morbidity has remained 
significant, chiefly because of poorly controlled bladder and bowel 
functions [1,2]. In underdeveloped countries where medical resources 
are limited, no significant progress has been reported on the 
mortality and morbidity of SCI survivors.

Another huge population with neurogenic voiding dysfunction is 
children with spina bifida which effects one per thousand newborns [3]. 
Despite rigorous pharmacologic and surgical treatment, incontinence, 
urinary tract infections and upper tract deterioration remains 
problematic. The combination of pharmacological agents, surgical 
bladder augmentation and clean intermittent catheterization has 
limited success [4].

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ѧݽͨѧѧԺԺĿ

ߣ

2005-2009ڡѧĹ70ƪѧУѧ
ԺõĽ20ԪңЩ»ƺţ

1ݽͨѧѧоָʦ2006
2ϡƱӦо, ʡУƼȽ
һ2008
3Salen˫뿻弰ɽĺϳɡṹо, 
4ʡУƼȽһ2008
5ȫｵľ춬ƼӦо,
6ʡƼȽһ2008
7ݽͨѧгɹȽһ2007꣩

ݽͨѧѧԺվͻȻָ˽Լڸ־Ϸ
ȫɾ˵ʲô˼

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ɽѧø

ߣjxh

ɽѧУӻλѧߣ㾯Чȡ
ɽѧѧٵĲ鲻ֵùУѧϰ緽
ָģߵĶвٹͬߣЩͬ߸óеʲô
أɽѧӦöԴش

ҲΪͬǶ٣Ϊϳ׷Ǹ߻
ٶҪߣһر̫ͣ˵
˵ͨ˵Щͬ߶֪ԼߣҲ
ˡĿܾǣͬǸûЩ£Ҳ˵Լ
ûκι׵ˡȻû뵽
ҲΡ˻ЩͬǣǻȻΪ
ûзաԾɽѧбҪԹͬҲطֱ
洦ɽѧΪԼѧ罨춨̤ʵĻҲΪ
Уõİ

ӾɽѧĴļУ֪εʦӻôӻʦ
˭أӻٿţ֡ѧE Ͻ
ҪлѧѧԺѧƴͷڡ2003꣬
ھڡѧEϷģĻУѧѧԺ
Ҫɹ(*)ǲ˵ӻڽ̵ģӻ
󲿷ڵΪУʧڼλҪеġ
ڻѧѧԺĵλӦԼڴ¼ϵĴ봦
֣ʵжȹʧ

* Zeng XR, et al., The binuclear copper(II) complex 
&micro;-chloro-&micro;-methoxy-bis [chloro 
(di-2-pyridylamine)copper(ii)]Acta Crystallographica Section E, 2003, 
E59, m1168-m1170

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ԷɾɽѧĲ

ߣrt

緽˵ɽѧνĴᵽĽ3.2
Ԫһƪƪôĸ

ʵǾɽѧķű࣬SCI¼ڸߵ
ÿƪ10000ԪһĲ٣5000Ԫÿ꿼˷Ľ
ʵþʵݻҿ϶ÿƪ¶Ӧõõ˽˭
أ

ѧУʵͼǰѽ쵼жѧУƵĲ
ԼĽ̹ٶӦóеΡֶʵ˵ϸʵ
Լҳ£û׸Ľⲻ֪٣
Լ̹٣ѧУ٣Լ䷢ļݶˣҲ̫
˰ɡ

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

Ϊҽ汳˵ѣϳν̵ˣ

ߣ

XXX쵼£ѧҶαѧҡǰдѧǮѧɭ֤
ĶĴҽ人÷֧Фйα
ѧʵ飬лҽѧ᳤ɽΪҽ飬˵H1N1
ҩо()Һܷϼһϳ˵ҽ
עؾֲҽ壬߽ƻáƵ
УҽѾǸƣĳֶΡԣҽϿ
߸ΰЧ

ϳ˵ġҽϿ߸ΰЧĿѧʵ
ʵоڹʲôطظ88ˣ
˻ҽ汳Ǯѧɭ÷һһҪڿѧ
ϱȨҪϱһȷ60ǻ˿ѧ
εĻ88ʱѾͿ֪ԼʲôʱΪ˵ʲôʱ
Ϊѧ˵

ƨҽϿ߸ΰЧǶйҽѧѧ
ͱѡ

һӢeMedicineԭԸΰPrimary Hepatic 
CarcinomaĴԭشһ⣬˵ġҽ
Ͽ߸ΰЧ͹϶ԭԸΰĴԭ
֤ܹЧ

ҽͷ˵ѣһͷǲξͺõĲУһͷҲ
õĲΰҽİ취ˣ˵塱
ͷĲЩ˾оȣξҪµĲҽͱ߳ȥˡ

88ϳǰҪӿѧݣΪҽ汳˵ѣȵ
ˡϳν̵ˣ

ԭԸΰʺͲ֢Mortality/Morbidity
Cure, usually through surgery, is possible in fewer than 5% of all 
patients.ͨĲ5Median survival from time of diagnosis 
is generally 6 months. һ6¡Length of survival depends 
largely on the extent of cirrhosis in the liver; cirrhotic patients 
have shorter survival times and more limited therapeutic options; 
portal vein occlusion, which occurs commonly, portends an even shorter 
survival.ӰҪǸӲžComplications from 
hepatocellular carcinoma are those of hepatic failure; death occurs 
from cachexia, variceal bleeding, or (rarely) tumor rupture and 
bleeding into the peritoneum.֢ɸ˥ԭжʣ
ųѪѳѪ

Medical CareҩưϵͳSystemic chemotherapy
Surgical CareưָгPartial hepatectomyֲ
TransplantationֲLocal tumor ablation
Available treatment options depend on the size, number, and 
location of tumors; presence or absence of cirrhosis; operative risk 
based on extent of cirrhosis and comorbid diseases; overall 
performance status; patency of portal vein; and presence of metastatic 
disease.

Before instituting definitive therapy, it is best to treat the 
complications of cirrhosis with diuretics, paracentesis for ascites, 
lactulose for encephalopathy, ursodiol for pruritus, sclerosis or 
banding for variceal bleeding, and antibiotics for spontaneous 
bacterial peritonitis.ڶǰӲ֢
̳鸹ˮԲɦӲͰƾųѪÿ
ϸԸĤס

Follow-up
Further Outpatient Careúﴦ
Monitor the progression of disease or adequacy of treatment with 
imaging studies every 2-3 months and LFTs and AFP monthly or as 
appropriate for the stage of disease and patient's performance status. 
These interventions, however, have little or no impact on prognosis 
for survival and therefore should be performed in accordance with the 
patient's functional status.

Deterrence/Prevention/Ԥ
Patients should avoid alcohol and other hepatic toxins because 
prognosis is related to worsening cirrhosis and tumor stage.˲Ҫ
ƺͳԶԸжԵĶ

Complications֢
Symptoms of hepatic failure may signify tumor recurrence and/or 
progression.˥֢״

PrognosisԤ
Overall prognosis for survival depends on the extent of cirrhosis 
and tumor stage, ԤҪӲ̶Ⱥ/which then 
determine the appropriate treatment. Patients able to undergo a 
curative resection have a median survival of as long as 4 years; 
patients who present when they are too ill to be treated have a median 
survival of 3 months.

Patient Education˽

Medicolegal Pitfallsй
Consider hepatocellular carcinoma in any person with possible risk 
factors who develops symptoms of liver disease, such as unexplained 
jaundice, increased abdominal girth, or pruritus.иβ֢״ı㣬
ΧӣɦĲҪųΰ
Family members of patients with hepatitis B infections should 
undergo screening for the virus.Ҹβ˵ļҪҸΡ
Consider screening of patients with cirrhosis, especially those 
with hepatitis C infection.ӲҪųΰ
Special Concernsرע
Screening for hepatocellular carcinomaŲΰ
Despite the widespread use of screening and surveillance programs 
for hepatocellular carcinoma, the efficacy and cost-effectiveness of 
screening programs for at-risk patients is unclear.ĿǰΪΰŲ
Ч/۱Ȳȷ
In general, the annual incidence of developing hepatocellular 
carcinoma in the setting of cirrhosis is approximately 1-4%. Screening 
studies have shown that, although lesions may be discovered at an 
earlier stage, the lack of curative treatment options in patients with 
cirrhosis may not lead to improvements in survival.ÿ1-4 ĸӲ
˷չɸΰڷ֣иӲĲ˵Ĵڲơ
Patients with chronic hepatitis B without cirrhosis have a much 
lower annual incidence of developing hepatocellular carcinoma of 0.46%. 
ҸβûкϲӲչɸΰÿ0.46%иӲٺ
ࡣThe incidence of hepatocellular carcinoma in patients with chronic 
hepatitis C without cirrhosis is even lower. βûкϲӲ
չΪΰĻ͡Screening programs using AFP and an imaging 
modality in patients with hepatitis B or C without cirrhosis is not 
cost-effective given the low incidence of hepatocellular carcinoma in 
these patients and the high cost of imaging techniques.
Survival advantage with screening in these at-risk populations has 
not been demonstrated. The retrospective screening studies that have 
shown modest survival advantages are confounded by lead-time and 
length-time bias.
If screening is to be undertaken, AFP should not be used alone as 
a screening test. Instead, AFP should be combined with an imaging 
modality (ultrasonography, CT scan) to improve sensitivity and 
specificity.

¼20091231
ҽӦֶ 

йѧԺԺʿڶҽѧϺεҽԺԺϳ
ΰһȫԼڸ౾ľֲ֡ҽעؾֲҽ
壬߽ƻáƵУҽѾ
ƣĳֶΡԣҽϿ߸ΰЧ 
ڽɵڶҽѧεҽԺ졢ΰҽҽԺа
ġΰҽۺ̳Ͻⷬġ

ڶҽѧϺεҽԺ÷Ⱥǿڣ
ϺѧҽԺҽϿ³ڣлҽҩѧ
ֻḱίԱ֣ΰڵרңҽۺƸΰ̳չۡ
֣ΰΪȫԼҪҽҩƣơ
ҩơʳơλһۺơ÷˵ǴҽӶ
ٴ鷢֣ҽҩȷܶԻʵʩ
ٽιָܻĽܣ

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

¼뵽

ߣ

20091230˿ǳϾѧУ걨ҿγ١
ʵܴΪйĸУǸ൱ձ顣ǾƷγ
ˣ粩ʿ˶ʿ㣬оأִСĿصѧơ
൱ձشƵΪУΪ˶񾭷ѣߡˮƽ
ԼСȫУ֮ΪɣԼ͡ŶӾ
١ٵķʽƴճɹԭרҵԺϵ޹صĽʦ
ȫ걨ʹãѻѸָרҵԺϵ޹صĽ
걨ʹãѸָרҵԺϵ޹صصѧ
ƣĿ걨ҪڸУԴʦ
ζһҲ⡣ǶԴϣȴУ
˷ǳá

1Ӿ˹ٱλЩĿֵĶǹ٣ǹ
ҪӰˣЩٻЩԴ󣬼˽
һӹٽʱ˽һ걨˲ţרһָѧͷʱ
˽һȡźʱڸУԺϵרҵûгִ
ٵģһ㶼ԴƶΪʲôЩĿ֣Ϊٿܰƽ
׳桰ءٿƿصĹԴء
¼˵һǽĽѧָίԱίԱΣ
ס㡱ίԱʵ¼û̸ѧǿ
еȨίԱ̸ָʲôûУ
źıꡣձĽʦȻûЩȻûʲôĿȻû
ʲôȵʱʱձʦЩȻһأ
̭ĳУһλУһβѡϣţ˵Ŀģ£
ĿٵġûеģĳУһλУȡĳĿԺϵջ㱨Ժ
ϵһŬĿʹմﵽǮʱܲм˵Ǯʲ
ôҸ˵ĿǵǮࡣԺʦ쵼˽·Ȼ㲻
УձʦôྭѡȻһЩԱ
ٱλԴƽȴԭΪȻ
ЩҲҵǸɣǵķȨһǿܵġڿоѷ棬
ְıûְҪࡣ־ʵԴɵġ
Դ㣬ܾͻڸɶȡϣ⡱
й걨20091221գŮʿ˵öɣԴ
ġʵԶŮʿ˵ȨʵŮʿ˵ǽ
ܽ⡣󣬸ࡢ㡣

2ƻУ԰гɥʧѧڸУѧͨȨԼ
ҪΪ˴Դ˷ϵĽһȻ´ѧڲ
гͨʦѧУԱ֮ĶرһЩвܣûеٻ
ԴĽԱ֮ĶѧٿЩõԴųѣֲ
ţ㡰˳߲ߣѡߣǮߣߣ
ǮĳѧǰȡĳĿϣһЩ쵼һЩںרҵĿ
صѧΪʹãĿֺԸɾܾЩʦ
Щʦʹãɱ˴ìܼڴѧ൱ձ飬ñ˵ĳɹ
ĿѧƵ㣬Դֺûб˵ķݡǿȡɲͻ
Ź֡ɶǣЩٻЩԴ£ûʱ
£µ¡ܹٷֵԴ£ȻΧŹٽɰ
ЩԴЩе˵˽ڡ˲ţЩ顱
˵жͨͨеģеȫЩԴ
¸¸ͨġ£У԰ԸūţԸ
ߣԸֵԽԽࡣֽʦԽ࣬˸ᶨ׷
߾Խ٣ɿѧʶڴѧ¾ļ԰Խ
Խϡȱʧȥ԰ѧͲǴѧѧڵ˾ͻԽԽ
ܡе˹ϴ̸Ʒ˽±ش̰ʴҡα
桢̰߳ڴѧڲҲ˳¡ԣŮʿҪԹ
ȫ

3Ťѧ۱׼оɹˮƽ¡ڸУһԽԽ
ձһʦˮƽǿöپѡʵĿ
ֻһо߰ҪʸĳоǱоߵ
оɹǳɹġǷǳɹоɹҪͨͬǿ͹˽ĵ
ۣҪķƶȣеĻҪͨʵӦõЧԼ顣˵
ǷĿ۽ʦɾ͵ı׼ȫԡĿ뾭Ѿɾ͵
ǲƵģѧ۸ĶʵʹеĹٵ
Ŀ㲻κο͹۵ۡΪоʸ֤ǽе
оϣʵܷӳʵʵо״
ҪǹٵĻһж̸ϡκоҪһֲ֧ſ
ԽϺõؽУرеѧƱͨʵоͨշѲܷ
ٵĿɰ˱оĿܣγһȨ¢µľ
Ȩ¢µľʹ۱׼ǿ͹۵ģҲܱ֤ɹǺϸġ
Ϊܱ֤ʤоߴоܱ֤µõо
ˣȨ¢µѧоɱزˮƽµ⡣

ЩйĴѧҪΪһѧҪǡȥ
ٻֻСȥٻпܷչſܲʵ֪ѧ

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ɡϴѧֹڹϵͳǡ뵽㽭ѧУ

ߣ

˿Ͽϴѧֹڹϵͳǡһģ˵
ϴѧһЩ쵼еְȨ¢ѧԴ⣬ʵ
ѧձڵġ㽭ѧڡ

㽭ѧУÿΪ㽭ѧһѧ
¶㣬ѧоĻɫ06ԡѭ
շ缯ɼùҿƼȽΪѡԺʿһ
Ҫ롣ϧ09ԺԺʿʱԺʿ֪ĵϸ
顣

УµЩʿʶ1/10

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ߵƻй̬谷

ߣˮ

¹̷¼ʹļסܺҵƲ
ܵս̵ĽѵǾܰǡڻ
Щ⣬ĳЩŪΪĹϢݡ
һֿԶԸ⣬̷еʵʵʺӼȻ
谷ķʹòûܵӦеֹ׷õйزŵĬ
Ͽɡ󣬼չΪȫҵϰΪ׬ǮܡȻٵ
ǼٵģαװһҪȥڴйҵԵʧ֮
ڸ谷ƭ˵ġѧƷ

ͬΣյ飬Ŀǰڷй̬ϡȱʵ
ǵ̬ȣһЩйĻѾ˽ġ谷
谷ĳЩҷһһЩߵҲ
ҥ߲ٷĻر˿ҥйɫĳƺţ
Ϊҥ谭йķչй쵽⼸ʮԪĸ߶
𡱡ȻЩŵƭ£йĻ⣬ȴò
ԽԽصѡ

磬ŭҹһЩˮ翪мƻĿҥ֮
йòĿú̿ܶط̬ܵƻ
ңصԴṹ񻯣Ҳǹھˮƽߵ£
ŷŹȻʹǹҵľ÷չˮƽ
еӦеļη޴ìܡڸոձĻϹ
ܵУΪʸ֮ġȻƺûע⵽ҹе
ˮԴͻÿԼ15ڶֶ̼ء룬Ҳ
һȿˮ磬ÿ15ڶֵ̼ŷšǹҲ
ΪһŵŷŹңǵú̿ɾ
ǵĿѾôҡǵ̬ǰ
ôء

عʷΪ谭йˮ緢չĳЩ߱ҥ˵ˮ翪
ƻ̬ǣ߱ȫ翴ʵˮ翪̶ԽߵĹ
Һ͵̬Խáǰ꣬ĳЩ߱˵ŷͣ
ֹκˮӵĽ裬Ѿ˲ʱǣܹⷢҵļ
л趼Ѿͣ״̬Ȼʩڡ
ˣĿǰȫ˲ɺӵʵǣܹȡʯԴ
ŵĿԴٷ֮ʮˮ磬ңͳˮ
ľֻӣҲûмٹЩƭ˵ҥԱʵҴ
αרҺͻһˮԴ40%йˮ
翪سʾߵҥԡ񶾵˵йˮ翪
̬ѡ

źǣ谷ܼνһ͵αݵ
ҥԣǵȴרҵԱн¶ȥڹα
֯ϲ߻¡һƾҥ𣬾ȻԽҷѲ
ʹ˲ŵĴʻ㣬Ȩϡйʷϵһҥ߿ظ
ҥȨд˰ķҲйزΪ谷ƭԺ
һΪҥԵʲôáˣٰԼ
̽¶ҥԵĲ£ɽҥҥ߸֮ѧۡɴ
ҥʹ ֪ܡʡ͡Ϳ桱δʻ
ĲΥ

ڷͥеĹУҥ𲻵òͥ˵ԼҥΪ
ĸ֤ݣܽҥ߱ȲҡָȻ
ڷټְҥѧ۵Ĺ£ҥ֮ͥ2009
78վȻٴԡˮ翪ʾ ̬֮ǡ
ıҥйˮ罨衣Ȼߵķͥϣҥߵͥʷ
ҥߡ֪ʷҥҷչΪһ֪
ܡĺͿ桢ĻӦһƻյų
һնķŻԱ֮⣬˭֮ܶͥ󣬻Ҫ
ҥΪȷĽͣȻܷͥúͿķٺҥ
Զԣ޵ݡǣй˾ܵһصǣоݿ
ԺͷͥеĽɡ

𷨹ٱҥߵΥУйǵҥ顣
Ϊףҥʤסйʱġ2009йʮ󻷾¼
УȻ˴۽İѡйרҰʤߡΪһ
¼йʱ˵ʽȨףʵǻ
רҵĽ˵ȷ٣Ȩֻʽʵ
רҵĽǣ˵ʲôרҵ
ĽأԼûеǣǸ¼Ҳѷ
֣Ȼҥ¶ҥԵĽʵǵĽ

۸˵⣬˵˼ǣרڼıǡǡ
˼ߵרҵϡ߼ΣǣϵҲǸܺõ
ѣҪ飬Ҫڽרҵ

͹۵˵оȷ˼רڼıǡǡ˼ߵרҵ
ϡǿԿ͹۵ķר¶ҥûУȻû
СǷٻо鶼˿ܶҡרṩ֤ݵʵԡôΪʲ
ô͹ʵȻڼߵġרҵأĹؼĿǰ
йǵ֡רҵ񡱼ֱ̫ˡⲻǽҥļ
ɣһøֹϵ˾ġйǡר
ҵͺֱ˲

¾ǵǰйɫƭ˵谷ÿƼһ
ҥƭ˵ĻߣܵõĳЩͥоⱣȻ
վǼٵģܹʲôȨͬ谷Ͼǵ
ʣҲܸı͹ʵνĿǰҹ󲿷ֺˮԴ
̶ȸߴϣĴϵϵһЩˮԴ̶
ߴ͡йˮ翪ʾߡ˵ǲ۲ҥ
ƭڸ˲ʹĴ֮ԿƼ谷̷Ѿ
Ȼȴ֪ǹҵ̬Ҫ
ĴۣǲʶйΣأ

ҥߵʤߣһλѵһ
ԵĶ

谷ÿƼ
ҥõͥĹ

йɫ

ЩȻϸһ벢ûее
Խܰˡʱ˿̣Ҫ裡

йߵй̬谷

:ο
йʱ2009йʮ󻷾¼
йרҰʤ
¼£գһƾձӵеһм
Ժо顣ойˮ繤ѧḱ鳤Ųͥߣ
άһԭУоΪоⳡˮרҵĹ˾Լ
ʤ߻˾š
꣱£գڡһƾձϷ¡ˮ翪
ýˡˮרĹ۵ƣĿǰҹ󲿷ֺˮ
Դ̶ȸߴϣĴϵϵһЩˮԴ̶
ߴ
꣱£գŲͥˮ䲩ϷΪ᲻
Ҫ֪޳ܵɫ£ΪǡȻ͹Ҵչˮ
Ĺ߳ͼԴ˳ȫĶ衢̰
Դ硰зϡĺͿ桱֪ܡ
ʹĿäˡȣѧ۱
꣱£գ𵽱Ժϣ״Ų
ַͥȨꣲ£գðһ󣬸һо
ŲͥӦ𹫿Ǹ⳥𺦸ο𣲣Ԫ⳥֤ݱȫ
֤ѣԪѣԪŲͥһʤߡ
ŲͥһоеһмԺ
£Ժо飬άһо
йʱʽȨףʵǻר
ҵĽ˼ǣרڼıǡǡ˼ߵרҵ
ϡ߼ΣǣϵҲǸܺõѣҪ
飬Ҫڽרҵ

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ֵºӢ

ߣcocktail

һƪСӢĲֵ֣ºӢµ߲һ
£˳һ£Ҳͬ

Ժʿĸͽǲȱѧ淶ʶбĿİɣ

paper 1: The black water around the Changjiang (Yangtze) Estuary 
in the spring of 2003
author:  Bai Yan; He Xianqiang; Pan Delu; Zhu Qiankun; Gong Fang
journal: Acta Oceanologica Sinica, 2009, 28(4), p23-31
received: 8, Feb, 2009

paper2: 2003괺ںˮо
author: ǿƾ䣻㣻˵¯Ǭ
journal: ѧ31330-38
received: 2008-06-10

ƪµݣժҪͼΣȫһֻĺӢĵĲ𣩡

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ǻеĺֳɷ

ߣ

ĿǰٴУĳЩҽƴʩǳĳرĳЩսС
ҽܴĿǻֲǵһ̫ģҪ֪
õжģָϾͿ֪һһη룬д֮

ESC2008˨ָйھ

1868꣬TROUSSEAUǻԤ˨
ֱ2060ɾƤͷŵϵͳҪڴ30ŷ
ֲͨµǻǻڷѪ
˨γɣֲߵǻΡ

ܿԷԤ˨ã䲢֢Զڲ
࣬ٷѪ˨γɺѪ˨γɺۺ

Ĳ֢֢ڲֲ֢봦Ѫ˨
γɣԼ10Զڲ֢ٷѪ˨γɣԼ20
Ѫ˨γɺۺԼ40Ƿʱ䳤̣22Ļֲ
5ʱǻ339һЩΪֲһ
ʱȡԿȡֲ2ȡĿǰͳƱ
ܶʱڹʱ䣬Զڲ֢Ϊ10λ
Ѫ˨γɡǻ׼ȷķ/Ϊ󲿷ֲ
ϲȫȱٷ˨Ŀ͹ۼϡĿǰΨһ
У400Ѫ˨γɣ򲻰˨ĻߣΪ飬һ
ػͷӸؼӿڷҩƣһпƲֲǻ
ʼ12ʱķ˨Ϊ4.8ֲΪ1.1P
0.03; Բ졣12ʱʽΪ
2.5ǵ54Ϊ˨ֲ5Ϊ
֮ٴ8ͳƱֲ벢
ʻ棬ٷ˨Ѫ˨γɵķӡ

ĿǰƼھѪ˨˨֢Ļгֲǻ
ڿɺ͸ٷ˨յĻߣƻ
ʹáҲڽԤڵ㷺Ѫ˨γɵиһɰȫʹÿ
ӦʱȡĿǰǰհ֤ʱ䳤
ȡ

Ŀǰ֧ΣĹɾмγɵδھ
Ѫ˨Ѫ˨γɲгʹþһಡбУ
еƺ˨ķʽϵͣΪ3.3Ƶǣ˨Ʋ
ԤֲӦ֢

Ŀǰҽѧѧиص㣬ýνĳЩҽƲ
Իʲô洦ʵ˵ˣԻ߿û̫ô
ҽľõǷǳԴҲ֮͡ǻãֻ
νѧѾԼܶ࣬ܶҪǫۣ̃
Цָ̫ģ֢ΣԶԤ˨ĵ棬
ѧǽȥƶϣһôˡ

ⲻΪ˴ҵǴٽҵĹ淶
ŵηǳ

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

˵¡ַҽ¹ʡ

ߣ

Сַҽ¹ʡ˵

дңǴĵһлȻԣǵڶ
ֲ˸ְĴ˵죬侭ǣλ
λȫ룬֯ҲܸԭĤ˺ѣ˺ѣСѪ
˺ϣЩӦüġûȫ֯Ǹܴʣ
ŪͺͿ˸ְ塣ûƲжǲܵҽ
ġ

µڿǻߵҲûйۣҽ֪Ҫ
ȫԲŪȵ£ϻ


ġѧᵽҪѹõٲܰѹȫ
飬ͲˡλҽĴǰѹˡ

дƪʱ뵽һģ޵ˡǸ
ܴʡļ֡Բ

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

汨ͷĳϮ

ߣ

˿µǳİ汨ġκ֮ĹʵǳϮ
̳һƪ¡·ֵĲܲĹֳɺϰ滪ϻ¼IDС֮֡
£
http://www.tianya.cn/new/Publicforum/content.asp?idWriter=1912883&Key=170751604&idArticle=1774122&strItem=free&flag=1

Ȼų֮֡ǡ汨ġһ仰

Ҫǳͷǹд κ֮ͷǹǡĹ͸
ˡ

ȴǡġԭںĸ

汨ͶУò˾͸ճκø
ꪡκοʯЩԳ־հճͼ࣬
뿴ϸǡáǡáߣĹҲٶȰٿд
Ĺɼ顤Ŵ֮ߣڹ֮
׼гȡĹ֮塣

һ⣬ԭָˣ汨ͬѧѵû

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ԺרһӦܲĹɣҵʿ˵л

    籱£յ磨߰季йءٲܲĹ
ۡйѧԺѧίԱйѧԺоԭ
κѧھܼרʱ˵ܲĹ֤Ѿ㹻
ǡҵʿ飬Ͳ˵лӦڿѧѧ⣬
Ҫ˵ҵڵĻѧ淶Ļ

    ˵ܶνġҵʿרҡѾơ磬
տѧԱĹʷר߷ΪûгĹ־򰧲Ǵ˴ھ
ӲˡͲҵڵĻĹ־ڶǲĹģ
κʱڲеġǰӦòһ鶫˵Ҫ⡣

    ڿСκʯƵʣ˵ʱһУ
ʯƣСκУУǱߵġǸǣ
ģô֪ǰձǸģҪԼ뵱Ȼ

    ⣬Գʯƿֲα⣬Ӧ˵
˵ֵݵ㲻κϱʱڵģ˼ҹѧңйѧ¡
ʡ￼оԱ±ԣ˵ǡº;ɲǰһǰ
һ塣ĹǼٵİɣµİɣҲǣǰİɣ
㲻Ϊɳѳ˿·ã˵ôǣǰ
أʼıڻ԰ͷϣЩ˵϶Ǽٵģ
ôôܸͷأ

    ǿѧſѧӦѧƷΧ⣬ѧʷղ
רڿ򲢲Ȩԡܶý屨˵ҵڵʿĸ
ҵڵģҵҵһ˵ҵʿ˵лҪ˵ҵڵĻ
ѧ淶Ļ

    ڣģΣ˵иãʹûУڵ֤Ѿ㹻
ģΣҪйͷҪǹͷı̶ȡȾ
̶ȡ˸˭ȶԣڵĲܲٺǲǲܲٺƴԺܲٵԽͿ
ԽףǼ鳼˭ĺھѶȺܴ󡣡
ΪģΣֽ׶Ҫ۵ʱǱġ 

(XYS20100102)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

һΪ˰޷˿վĹ˽˿վĶ̬ؿ
˿ʼбxys@yahoogroups.com

ʼбÿ췢һ˿վ¸µϣÿµ׷һÿ
Ŀ¼ʼбĶμ롰˿֮ѡ
ʼбxys_friends@yahoogroups.com

ù䶩ġù䣬ܿ޷յ
Ƽ䣺yahoo.com, hotmail.com, gmail.com

ġ˿ʼбĵ䷢һհż

xys-subscribe@yahoogroups.com 

塢ͣ˿ʼбͣ䷢һհż

xys-unsubscribe@yahoogroups.com 

Ͷxinyusi@yahoo.comôıļͶ塣

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

